Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor κB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women

Jung Gu Kim, Jung Hwa Kim, Dong Ock Lee, Hoon Kim, Ja Yeon Kim, Chang Suk Suh, Seok Hyun Kim, Young Min Choi

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

OBJECTIVE: To investigate changes in the serum levels of osteoprotegerin (OPG) and soluble receptor activator for nuclear factor κB ligand (sRANKL) after estrogen plus progestogen therapy (EPT) and to determine their relationships with changes in bone mineral density (BMD) and bone turnover markers in postmenopausal women. DESIGN: Serum levels of OPG, sRANKL, and bone turnover markers, such as osteocalcin and type I C-telopeptide breakdown products, parathyroid hormone, calcitonin, calcium, and phosphorus, and BMD at the lumbar spine and proximal femur were measured in 297 postmenopausal Korean women. In all, 143 women were treated with sequential EPT for 1 year. RESULTS: Before EPT, serum OPG and sRANKL levels and RANKL/OPG ratios were not related to BMD at the lumbar spine and proximal femur, except for a negative correlation (r = -0.13, P < 0.05) between serum OPG and BMD at the trochanter. Of the bone markers, serum parathyroid hormone alone correlated negatively with serum OPG (r = -0.19, P < 0.005) and positively with serum sRANKL (r = 0.23, P < 0.001) and sRANKL/OPG ratios (r = 0.28, P < 0.001). After 6 months of EPT, serum OPG and sRANKL levels were unchanged, but sRANKL/OPG ratios and serum levels of bone turnover markers, such as osteocalcin, type I C-telopeptide breakdown products, and phosphorus decreased significantly. The 1-year change in BMD at the lumbar spine and proximal femur after EPT was not found to be correlated with basal levels of serum OPG, sRANKL, and sRANKL/OPG ratios and their changes at 6 months after EPT. After 6 months of EPT, changes in all bone markers were not associated with changes in circulating OPG, sRANKL levels, and sRANKL/OPG ratios. CONCLUSIONS: After EPT, sRANKL/OPG ratios in the circulation decreased, but changes in this OPG-sRANKL system have no association with changes in any bone marker or BMD. The OPG-sRANKL system in the circulation might be involved in reduced bone resorption after EPT, but does not seem to be clinically useful for predicting BMD or bone turnover status and bone response after hormone therapy.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalMenopause
Volume15
Issue number2
DOIs
StatePublished - Mar 2008

Keywords

  • Bone mass
  • Estrogen plus progestogen therapy
  • Osteoprotegerin
  • Postmenopausal women
  • Receptor activator for nuclear factor κB ligand (RANKL)

Fingerprint

Dive into the research topics of 'Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor κB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women'. Together they form a unique fingerprint.

Cite this